Skip Navigation

Ursula A. Matulonis, MD


Medical Oncology

Make an Appointment

Physician

  • Director, Gynecologic Oncology
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Gynecologic malignancies
  • New therapies for gynecologic cancers

Contact Information

  • Appointments(617) 632-2175
  • Office Phone Number617-632-2334
  • Fax617-632-3479

Bio

Ursula A. Matulonis, MD is Medical Director and Program Leader of the Medical Gynecologic Oncology Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. Her research focuses on targeted therapies for gynecologic malignancies, with a specific interest in the genetic changes in ovarian cancer and how that can lead to rationale targeted drug selection. Dr. Matulonis is the Principal Investigator of several clinical trials and translational studies for ovarian cancer. Dr. Matulonis is a Co-PI on an ovarian cancer SPORE project entitled “Identification of Oncogenic Mutations in Ovarian Cancer,” and a Co-PI on the project “Genetic relationships between breast and ovarian cancer” that is funded by the Breast Cancer Research Foundation. She is also a past recipient of a DF/HCC Ovarian Cancer SPORE Developmental Grant entitled “Genetic Fingerprinting of Ovarian Cancer.” 

Dr. Matulonis serves on the National Comprehensive Cancer Network Ovarian Cancer Recommendation and Guideline Committee for both ovarian cancer and for the treatment of anemia, the Gynecologic Oncology Group Quality of Life Committee, a member of The Cancer Genome Atlas Project (TCGA) Endometrial Analysis Working Group, and is Medical Director and Board Member for the non-profit organization Ovations for the Cure. She is a recipient of the Dennis Thompson Compassionate Care Scholar award, the Lee Nadler “Extra Mile” Award, and was named one of Boston’s Best Physicians in Medical Oncology by Boston Magazine numerous times. She serves on the editorial board of the Journal of Clinical Oncology.

After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at Dana-Farber.

Board Certification:

  • Internal Medicine, 2000
  • Medical Oncology, 2003

Fellowship:

  • Dana-Farber Cancer Institute, Medical Oncology

Residency:

  • University of Pittsburgh, Internal Medicine

Medical School:

  • Albany Medical College

Recent Awards:

  • Partners in Excellence Award, Partners Health Care 2010
  • Lee Nadler "Extra Mile" Award 2009
  • "Boston Magazine" Best Doctors 2009
  • Partners in Excellence Award, Partners Health Care 2000
  • Dennis Thompson Compassionate Care Scholar, Brigham and Women's Hospital 2000

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions

Research

Clinical Trials in Gynecologic Malignancies

The Medical Gynecologic Oncology Program serves as the infrastructure for clinical and translational research at Dana-Farber Cancer Institute.

Our research involves testing novel drugs and biologics in newly diagnosed as well as recurrent gynecologic tumors: ovarian, endometrial, cervical, vaginal, and vulvar cancers. A list of ongoing clinical trials is available via our website.

Our integrated team of medical oncologists, gynecologic oncology surgeons, radiation oncologists, gynecologic oncology pathologists, clinical research team, and basic science researchers is immersed in a number of translational projects.

Examples of ongoing projects in 2010 include the expression profiling and genotyping of ovarian cancer, the study of circulating tumor cells in ovarian cancer, investigation of HER3 expression and signalling and therapeutic potential of HER3, and the study of the PI3 kinase pathway in endometrial cancer.

Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson JD, Sampath D, Mills GB, Brugge JS. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nat Commun. 2017 Aug 28; 8(1):365.
View in: PubMed

Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 Aug 24.
View in: PubMed

Matulonis UA. Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary. Clin Adv Hematol Oncol. 2017 Aug; 15 Suppl 7(8):13-17.
View in: PubMed

Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget. 2017 Jul 18; 8(29):47154-47160.
View in: PubMed

Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15; 123(16):3080-3087.
View in: PubMed

Matulonis UA, Monk BJ. PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? Ann Oncol. 2017 03 01; 28(3):443-447.
View in: PubMed

Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017 03 01; 28(3):512-518.
View in: PubMed

Mirza MR, Matulonis UA. Niraparib in Recurrent Ovarian Cancer. N Engl J Med. 2017 02 23; 376(8):801-2.
View in: PubMed

Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. Clin Cancer Res. 2017 Aug 01; 23(15):4086-4094.
View in: PubMed

Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol. 2017 Apr; 9(4):253-267.
View in: PubMed

Howitt BE, Strickland KC, Sholl LM, Rodig S, Ritterhouse LL, Chowdhury D, D'Andrea AD, Matulonis UA, Konstantinopoulos PA. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology. 2017; 6(2):e1277308.
View in: PubMed

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118.
View in: PubMed

Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 Nov 17; 1(19):e87062.
View in: PubMed

Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016 Nov 22; 115(11):1313-1320.
View in: PubMed

Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, Kelley SK, Lu X, Choi YJ, Maslyar D, Humke EW, Burris HA. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov; 27(11):2124-2130.
View in: PubMed

Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1427-1433.
View in: PubMed

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 12 01; 375(22):2154-2164.
View in: PubMed

Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clin Cancer Res. 2016 Dec 01; 22(23):5651-5660.
View in: PubMed

Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov; 17(11):1579-1589.
View in: PubMed

Makker V, Recio FO, Ma L, Matulonis UA, Lauchle JO, Parmar H, Gilbert HN, Ware JA, Zhu R, Lu S, Huw LY, Wang Y, Koeppen H, Spoerke JM, Lackner MR, Aghajanian CA. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 2016 Sep 07.
View in: PubMed

Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 Sep 06.
View in: PubMed

Evans T, Matulonis U. Next-Generation Sequencing: Role in Gynecologic Cancers. J Natl Compr Canc Netw. 2016 Sep; 14(9):1165-73.
View in: PubMed

Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Sep; 14(9):1134-63.
View in: PubMed

Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res. 2017 Mar 01; 23(5):1263-1273.
View in: PubMed

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016 08 25; 2:16061.
View in: PubMed

Lee LJ, Howitt B, Catalano P, Tanaka C, Murphy R, Cimbak N, DeMaria R, Bu P, Crum C, Horowitz N, Matulonis U, Viswanathan AN. Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. Gynecol Oncol. 2016 Aug; 142(2):293-8.
View in: PubMed

Ritterhouse LL, Nowak JA, Strickland KC, Garcia EP, Jia Y, Lindeman NI, Macconaill LE, Konstantinopoulos PA, Matulonis UA, Liu J, Berkowitz RS, Nucci MR, Crum CP, Sholl LM, Howitt BE. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. Mod Pathol. 2016 Aug; 29(8):893-903.
View in: PubMed

Liu JF, Matulonis UA. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr Oncol Rep. 2016 May; 18(5):29.
View in: PubMed

Alvarez RD, Matulonis UA, Herzog TJ, Coleman RL, Monk BJ, Markman M. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecol Oncol. 2016 Jun; 141(3):405-409.
View in: PubMed

Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016 Jun 15; 122(12):1844-52.
View in: PubMed

Coleman RL, Matulonis UA. Precision medicine. Gynecol Oncol. 2016 Apr; 141(1):1.
View in: PubMed

Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98.
View in: PubMed

Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin Investig Drugs. 2016; 25(5):597-611.
View in: PubMed

Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016 Jun; 27(6):1013-9.
View in: PubMed

Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504.
View in: PubMed

Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep. 2016 Jan 26; 14(3):429-439.
View in: PubMed

Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvão VR, Berlin ST, Campos SM, Matulonis UA, Castells MC. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016 Apr; 137(4):1154-1164.e12.
View in: PubMed

Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016 Mar; 5(3):e1090075.
View in: PubMed

Liu J, Konstantinopoulos PA, Matulonis UA. Genomic testing and precision medicine--What does this mean for gynecologic oncology? Gynecol Oncol. 2016 Jan; 140(1):3-5.
View in: PubMed

Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015 Dec; 1(9):1319-23.
View in: PubMed

Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10; 33(26):2841-7.
View in: PubMed

Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23.
View in: PubMed

Liu JF, Matulonis UA. Bevacizumab in newly diagnosed ovarian cancer. Lancet Oncol. 2015 Aug; 16(8):876-8.
View in: PubMed

Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U, Goldberg MS. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. Biochem Biophys Res Commun. 2015 Aug 07; 463(4):551-6.
View in: PubMed

Lee JM, Trepel JB, Choyke P, Cao L, Sissung T, Houston N, Yu M, Figg WD, Turkbey IB, Steinberg SM, Lee MJ, Ivy SP, Liu JF, Matulonis UA, Kohn EC. CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. Front Oncol. 2015; 5:123.
View in: PubMed

Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W, Gaffney DK. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Jul 01; 121(13):2156-63.
View in: PubMed

Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015 Feb 26; 160(5):977-89.
View in: PubMed

Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res. 2015 Feb 15; 75(4):628-34.
View in: PubMed

Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 2015 Feb 15; 21(4):808-18.
View in: PubMed

Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Feb; 136(2):246-53.
View in: PubMed

Matulonis UA, Oza AM, Ho TW, Ledermann JA. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. Cancer. 2015 Jun 01; 121(11):1737-46.
View in: PubMed

Liu J, Matulonis UA. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res. 2014 Oct 15; 20(20):5150-6.
View in: PubMed

Konstantinopoulos PA, Matulonis UA. POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing. Cancer. 2015 Feb 01; 121(3):331-4.
View in: PubMed

Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14.
View in: PubMed

Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014 Sep; 134(3):478-85.
View in: PubMed

Barry WT, Birrer MJ, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam SR, Hurteau J, Luo W, Quy P, Obermayer E, Whalen C, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis U. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA5500.
View in: PubMed

Myers A, Barry WT, Hirsch MS, Matulonis U, Lee L. ß-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. Gynecol Oncol. 2014 Aug; 134(2):426-7.
View in: PubMed

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul; 15(8):852-61.
View in: PubMed

Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget. 2014 May 15; 5(9):2678-87.
View in: PubMed

Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest. 2014 Jun; 124(6):2611-25.
View in: PubMed

Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014 May; 133(2):362-9.
View in: PubMed

Picard M, Matulonis UA, Castells M. Chemotherapy hypersensitivity reactions in ovarian cancer. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):389-402.
View in: PubMed

Konstantinopoulos PA, Matulonis UA. Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Front Oncol. 2013 Dec 11; 3:296.
View in: PubMed

Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One. 2013; 8(11):e80023.
View in: PubMed

Lee LJ, Demaria R, Berkowitz R, Matulonis U, Viswanathan AN. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. Gynecol Oncol. 2014 Jan; 132(1):65-9.
View in: PubMed

Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, Matulonis U. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol. 2014 Jan; 132(1):55-60.
View in: PubMed

Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1199-209.
View in: PubMed

Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83.
View in: PubMed

Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013 Nov; 131(2):352-6.
View in: PubMed

Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013 Oct 01; 19(19):5485-93.
View in: PubMed

Gross AH, Cromwell J, Fonteyn M, Matulonis UA, Hayman LL. Hopelessness and complementary therapy use in patients with ovarian cancer. Cancer Nurs. 2013 Jul-Aug; 36(4):256-64.
View in: PubMed

Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
View in: PubMed

Townamchai K, Berkowitz R, Bhagwat M, Damato AL, Friesen S, Lee LJ, Matulonis U, O'Farrell D, Viswanathan AN. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer. Gynecol Oncol. 2013 Apr; 129(1):18-21.
View in: PubMed

Lu W, Matulonis UA, Dunn JE, Lee H, Doherty-Gilman A, Dean-Clower E, Goodman A, Davis RB, Buring J, Wayne P, Rosenthal DS, Penson RT. The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial. Med Acupunct. 2012 Dec; 24(4):233-240.
View in: PubMed

Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1339-49.
View in: PubMed

McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J, Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, Berkowitz RS, Aster JC, Matulonis UA, Dinulescu DM. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A. 2012 Oct 23; 109(43):E2939-48.
View in: PubMed

Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, Matulonis UA. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 2012 Oct 15; 18(20):5806-15.
View in: PubMed

Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer. 2013 Jan; 49(1):121-31.
View in: PubMed

Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
View in: PubMed

Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol. 2012 Oct; 127(1):63-9.
View in: PubMed

Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012 Oct; 127(1):141-6.
View in: PubMed

Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012 May; 10(5):628-53.
View in: PubMed

Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, Berlin S. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):41-6.
View in: PubMed

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12; 366(15):1382-92.
View in: PubMed

Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.
View in: PubMed

Godinez-Puig V, Frangos J, Hollmann TJ, Dryden-Peterson S, Matulonis U, Lipworth AD. Photo quiz. Rash in a patient with ovarian cancer. Clin Infect Dis. 2012 Feb 15; 54(4):538, 575-6.
View in: PubMed

Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One. 2012; 7(2):e30269.
View in: PubMed

Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, Schorge JO, Del Carmen MG, Matulonis UA, Horowitz NS. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012 May; 125(2):362-6.
View in: PubMed

Horowitz N, Matulonis UA. New biologic agents for the treatment of gynecologic cancers. Hematol Oncol Clin North Am. 2012 Feb; 26(1):133-56.
View in: PubMed

Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet. 2012 Jan-Feb; 205(1-2):34-41.
View in: PubMed

Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401.
View in: PubMed

Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012 Feb 01; 30(4):372-9.
View in: PubMed

Liu J, Matulonis UA. Anti-angiogenic agents in ovarian cancer: dawn of a new era? Curr Oncol Rep. 2011 Dec; 13(6):450-8.
View in: PubMed

Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
View in: PubMed

Viswanathan AN, Macklin EA, Berkowitz R, Matulonis U. The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol. 2011 Dec; 123(3):542-7.
View in: PubMed

Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, van Hummelen P, MacConaill L, Drapkin R, Hahn WC. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One. 2011; 6(9):e24433.
View in: PubMed

Coticchia CM, Curatolo AS, Zurakowski D, Yang J, Daniels KE, Matulonis UA, Moses MA. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol. 2011 Nov; 123(2):295-300.
View in: PubMed

Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011 Sep; 9 Suppl 4:S1-22.
View in: PubMed

Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote IB, Rustin GJ, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol. 2011 May 20; 29(15_suppl):5003.
View in: PubMed

Viswanathan AN, Szymonifka J, Tanaka C, Berlin ST, Campos SM, Horowitz NS, Lee J, Whalen C, Matulonis U. The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. J Clin Oncol. 2011 May 20; 29(15_suppl):5101.
View in: PubMed

Matulonis U, Tew WP, Matei D, Behbakht K, Fleming GF, Oza AM. A phase II study of ENMD-2076 in platinum-resistant ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5021.
View in: PubMed

Penson RT, Whalen C, Lasonde B, Krasner CN, Konstantinopoulos P, Stallings TE, Bradley CR, Birrer MJ, Matulonis U. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5004.
View in: PubMed

Liu J, Fleming GF, Tolaney SM, Birrer MJ, Penson RT, Berlin ST, Whalen C, Tyburski K, Matijevich K, Kasparian E, Roche M, Lee H, Winer EP, Ivy SP, Matulonis U. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5028.
View in: PubMed

Birrer MJ, Konstantinopoulos P, Penson RT, Roche M, Ambrosio A, Stallings TE, Matulonis U, Bradley CR. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5005.
View in: PubMed

Matulonis UA. Bevacizumab and its use in epithelial ovarian cancer. Future Oncol. 2011 Mar; 7(3):365-79.
View in: PubMed

Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL. Epithelial ovarian cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):82-113.
View in: PubMed

Cramer DW, O'Rourke DJ, Vitonis AF, Matulonis UA, Dijohnson DA, Sluss PM, Crum CP, Liu BC. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. Clin Chem. 2010 Dec; 56(12):1889-92.
View in: PubMed

Wright AA, Mack JW, Kritek PA, Balboni TA, Massaro AF, Matulonis UA, Block SD, Prigerson HG. Influence of patients' preferences and treatment site on cancer patients' end-of-life care. Cancer. 2010 Oct 01; 116(19):4656-63.
View in: PubMed

Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol. 2010 Oct 10; 28(29):4457-64.
View in: PubMed

Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010 Jul 24; 376(9737):245-51.
View in: PubMed

Liu J, Matulonis UA. New advances in ovarian cancer. Oncology (Williston Park). 2010 Jul; 24(8):721-8.
View in: PubMed

Dean-Clower E, Doherty-Gilman AM, Keshaviah A, Baker F, Kaw C, Lu W, Manola J, Penson RT, Matulonis UA, Rosenthal DS. Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients. Integr Cancer Ther. 2010 Jun; 9(2):158-67.
View in: PubMed

Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
View in: PubMed

Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia. 2010 Feb; 12(2):161-72.
View in: PubMed

Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010 Mar; 5(3):477-83.
View in: PubMed

Kornblith AB, Mirabeau-Beale K, Lee H, Goodman AK, Penson RT, Pereira L, Matulonis UA. Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. J Psychosoc Oncol. 2010; 28(5):451-69.
View in: PubMed

April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J, Cox D, Jones W, Rubio R, Holton K, Matulonis U, Quackenbush J, Fan JB. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One. 2009 Dec 03; 4(12):e8162.
View in: PubMed

Matulonis U. Review: erythropoiesis-stimulating agents increase mortality in patients with cancer. Evid Based Med. 2009 Dec; 14(6):182.
View in: PubMed

Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol. 2010 Feb; 116(2):168-72.
View in: PubMed

Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
View in: PubMed

Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010 Mar 01; 28(7):1215-23.
View in: PubMed

Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
View in: PubMed

Liu JF, Hirsch MS, Lee H, Matulonis UA. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol. 2009 Dec; 115(3):401-6.
View in: PubMed

Matulonis U. ACP Journal Club. Review: Erythropoiesis-stimulating agents increase mortality in patients with cancer. Ann Intern Med. 2009 Sep 15; 151(6):JC3-7.
View in: PubMed

Lu W, Matulonis UA, Doherty-Gilman A, Lee H, Dean-Clower E, Rosulek A, Gibson C, Goodman A, Davis RB, Buring JE, Wayne PM, Rosenthal DS, Penson RT. Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med. 2009 Jul; 15(7):745-53.
View in: PubMed

Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska L, Pereira L, Bryan J, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9.
View in: PubMed

Hirte HW, McGuire W, Edwards R, Husain A, Hoskins P, Michels J, Matulonis U, Sexton C, Michelson G. A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):5559.
View in: PubMed

Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9.
View in: PubMed

Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, Berkowitz RS, Mok SC. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7667-73.
View in: PubMed

Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
View in: PubMed

Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Grigsby PW, Havrilesky LJ, Johnston C, Lancaster JM, Lele S, Matulonis U, O'Malley D, Ozols RF, Remmenga SW, Sabbatini P, Schink J, Teng N. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008 Sep; 6(8):766-94.
View in: PubMed

Rodgers GM, Becker PS, Bennett CL, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Djulbegovic B, Garst JL, Gilreath JA, Kraut EH, Lin WC, Matulonis U, Millenson M, Reinke D, Rosenthal J, Sabbatini P, Schwartz RN, Stein RS, Vij R. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008 Jul; 6(6):536-64.
View in: PubMed

Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008 Sep; 122(3):574-80.
View in: PubMed

Penson RT, Kornblith AB, Lee J, Roche M, Atkinson T, Gibson CD, Horowitz NS, Krag KJ, Krasner CN, Matulonis UA. Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5590.
View in: PubMed

Matulonis UA, Berlin ST, Krasner CN, Tyburski K, Lee J, Roche M, Ivy SP, Lenahan C, King M, Penson RT. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5501.
View in: PubMed

Horowitz NS, Penson RT, Campos SM, Lee J, Kendall DL, Krasner CN, Berlin ST, Roche M, Duska LR, Matulonis UA. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523.
View in: PubMed

Mirabeau-Beale K, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska LR, Pereira L, Gibson CD, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. J Clin Oncol. 2008 May 20; 26(15_suppl):5528.
View in: PubMed

Amler L, Makhija S, Januario T, Matulonis UA, Strauss A, Dizon DS, Sliwkowski MX, Dolezal M, Tong B, Paton V. HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5552.
View in: PubMed

Krasner CN, Seiden MV, Penson RT, Roche M, Kendall DL, Young J, Matulonis UA, Pereira L, Berlin ST. NOV-002 plus carboplatin in platinum-resistant ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5593.
View in: PubMed

Gross AH, Cromwell J, Kornblith AB, Lee H, Li H, Pereira L, Penson RT, Matulonis UA. Effects of complementary and alternative medicine use on hopelessness in ovarian cancer patients. J Clin Oncol. 2008 May 20; 26(15_suppl):9598.
View in: PubMed

McGuire WP, Hirte HW, Matulonis UA, Penson RT, Husain A, Hoskins PJ, Michels J, Michelson G, Chiang A, Aghajanian CA. A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5582.
View in: PubMed

Castells MC, Tennant NM, Sloane DE, Hsu FI, Berlin ST, Campos SM, Matulonis UA. Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases. J Clin Oncol. 2008 May 20; 26(15_suppl):5526.
View in: PubMed

Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Penson R. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008 Nov-Dec; 18(6):1183-93.
View in: PubMed

W. P. McGuire, H. W. Hirte, U. A. Matulonis, R. T. Penson, A. Husain, P. J. Hoskins, J. Michels, G. Michelson, A. Chiang, C. A. Aghajanian. A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5582).
View in: PubMed

R. T. Penson, A. B. Kornblith, J. Lee, M. Roche, T. Atkinson, C. D. Gibson, N. S. Horowitz, K. J. Krag, C. N. Krasner, U. A. Matulonis. Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5590).
View in: PubMed

N. S. Horowitz, R. T. Penson, S. M. Campos, J. Lee, D. L. Kendall, C. N. Krasner, S. T. Berlin, M. Roche, L. R. Duska, U. A. Matulonis. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5523).
View in: PubMed

L. Amler, S. Makhija, T. Januario, U. A. Matulonis, A. Strauss, D. S. Dizon, M. X. Sliwkowski, M. Dolezal, B. Tong, V. Paton. HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5552).
View in: PubMed

M. C. Castells, N. M. Tennant, D. E. Sloane, F. I. Hsu, S. T. Berlin, S. M. Campos, U. A. Matulonis. Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases. J Clin Oncol 26:. 2008; May 20 suppl(abstr 5526).
View in: PubMed

K. Mirabeau-Beale, A. B. Kornblith, R. T. Penson, H. Lee, A. Goodman, S. M. Campos, L. R. Duska, L. Pereira, C. D. Gibson, U. A. Matulonis. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. J Clin Oncol 26. 2008; May 20 suppl(abstr 5528).
View in: PubMed

U. A. Matulonis, S. T. Berlin, C. N. Krasner, K. Tyburski, J. Lee, M. Roche, S. P. Ivy, C. Lenahan, M. King, R. T. Penson. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5501).
View in: PubMed

A. H. Gross, J. Cromwell, A. B. Kornblith, H. Lee, H. Li, L. Pereira, R. T. Penson, U. A. Matulonis. Effects of complementary and alternative medicine use on hopelessness in ovarian cancer patients. J Clin Oncol 26. 2008; May 20 suppl(abstr 9598).
View in: PubMed

C. N. Krasner, M. V. Seiden, R. T. Penson, M. Roche, D. L. Kendall, J. Young, U. A. Matulonis, L. Pereira, S. T. Berlin. NOV-002 plus carboplatin in platinum-resistant ovarian cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5593).
View in: PubMed

Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20; 25(33):5180-6.
View in: PubMed

P. ROSE 1, R. Edwards 2, N. Finkler 3, C. Duska 4, F. Cappuccini 5, T. Kolevska 6, E. Brand 7, K. Easley 8, J. Polikoff 9, U. Matulonis 4, C. Runowicz 1 1 Cleveland Clinic Foundation, Cleveland, OH, USA; 2 Magee Womens Hospital Of UPMC, Pittsburg, PA, USA; 3 Wright State University Florida State Cancer Institute, Orlando, FL, USA; 4 Harvard Affiliates Hospital, MA, USA; 5 Oregon Health & Science University, Portland, OR, USA; 6 Kaiser Permanente Hospital, Vallejo, CA, USA; 7 Sheridan Clinical Research, Pembroke, FL, USA; 8 Gynecology And Oncology Consultants, PC, St. Louis, MO, USA; 9 Kaiser Permanente, Southern California Medical Group, San Diego, CA, USA; 10 University Of Connecticut Health Center/John Dempsey Hospital, Farmington, CT, USA . PHASE 3 STUDY: CANFOSFAMIDE (C, TLK286) PLUS CARBOPLATIN (P) VS LIPOSOMAL DOXORUBICIN (D) AS 2ND LINE THERAPY OF PLATINUM (PL) RESISTANT OVARIAN CANCER (OC) . International Journal of Gynecologic Oncology. 2007.
View in: PubMed

S. MAKHIJA 1, D. Glenn 2, F. Ueland 3, M. Gold 4, D. Dizon 5, V. Paton 6, M. Birkner 6, C-Y. Lin 6, M. Derynck 6, K. Ng 7, L. Amler 6, A. Strauss 8, M.X. Sliwkowski 6, U. Matulonis 9 1 Univ of Alabama Birmingham, Birmingham, AL; 2 Sharp Rees-Stealy Medical Group, San Diego, CA; 3 UK HealthCare Markey Cancer Center, Lexington, KY; 4 The University of Oklahoma Health Sciences Center, Oklahoma City, OK; 5 Women and Infants Hospital, Providence, RI; 6 Genentech, Inc., South San Francisco, CA; 7 Dana Farber Cancer Institute, Boston, MA; 8 Roche Diagnostics, GmbH, Penzberg, Germany; 9 Medical Oncology, Dana Farber Cancer Institute, Boston, MA . RESULTS FROM A PHASE II RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL SUGGEST IMPROVED PFS WITH THE ADDITION OF PERTUZUMAB TO GEMCITABINE IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER . International Journal of Gynecologic Oncology. 2007.
View in: PubMed

U.A. MATULONIS 1, R.T. Penson 2, S.M. Campos 1, J. Bryan 1, J. Lee 1, D.L. Kendall 2, C.N. Krasner 2, S. Berlin 1, M. Roche 2, L.R. Duska 2, A.F Fuller 2, N.S. Horowitz 2 1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA USA; 2 Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA USA . PHASE II STUDY OF CARBOPLATIN AND PEMETREXED FOR THE TREATMENT OF PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER . International Journal of Gynecologic Cancer. 2007.
View in: PubMed

S.M. CAMPOS 1, S.T. Berlin 1, L.M. Parker 2, W.Y Chen 2, C.A. Bunnell 2, T. Atkinson 1, J. Lee 1, U.A. Matulonis 1, L.N. Harris 2, C.N. Krasner 3 1 Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 2 Breast Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 3 Gynecologic Oncology, Massachusetts General Hospital, Boston, MA, USA . PHASE I TRIAL OF LIPOSOMAL DOXORUBICIN AND ZD1839 IN PATIENTS WITH REFRACTORY GYNECOLOGICAL MALIGNANCIES OR METASTATIC BREAST CANCER . International Journal Gynecologic Oncology. 2007.
View in: PubMed

Matulonis UA, Kornblith A, Bryan J et al. Long term impact of chemotherapy in early stage ovarian cancer survivors. . Submitted to Gyn Oncology. 2007.
View in: PubMed

C. N. Krasner, M. V. Seiden, A. F. Fuller, J. G. Supko, M. Roche, D. L. Kendall, J. Lee, R. Berkowitz, S. Berlin, U. A. Matulonis, Dana-Farber/Harvard Cancer Center Gynecologic Oncology Research Group. Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5521).
View in: PubMed

M. S. Hirsch, J. Liu, R. Drapkin, H. Lee, U. A. Matulonis. ErbB3 protein expression in serous ovarian carcinomas of elderly women. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings. 2007; Part I. Vol 25, No. 18S (June (abstract 16026).
View in: PubMed

S. M. Campos, D. S. Dizon, S. A. Cannistra, M. Roche, C. N. Krasner, S. T. Berlin, N. S. Horowitz, P. DiSilvestro, U. A. Matulonis, R. T. Penson. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and müllerian cancers. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5517).
View in: PubMed

C. N. Krasner, M. V. Seiden, A. F. Fuller, J. G. Supko, M. Roche, D. L. Kendall, J. Lee, R. Berkowitz, S. Berlin, U. A. Matulonis, Dana-Farber/Harvard Cancer Center Gynecologic Oncology Research Group. Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5521).
View in: PubMed

Lu W, Hu D, Dean-Clower E, Doherty-Gilman A, Legedza AT, Lee H, Matulonis U, Rosenthal DS. Acupuncture for chemotherapy-induced leukopenia: exploratory meta-analysis of randomized controlled trials. J Soc Integr Oncol. 2007; 5(1):1-10.
View in: PubMed

L. Cripe, W. McGuire, M. Wertheim, P. Eisenberg, W. Stadler, R. Paquette, T. Logan, T. Zimmerman, D. Matei, U. Matulonis, XL999 phase 2 study group. Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(Abstract 3591).
View in: PubMed

A. Viswanathan, N. Horick, C. Tanaka, S. Campos, U. Matulonis, R. Berkowitz. Chemotherapy and radiation therapy in UPSC. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 1. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5535).
View in: PubMed

S. Makhija, D. Glenn, F. Ueland, M. Gold, D. Dizon, V. Paton, M. Birkner, C. Lin, M. Derynck, U. Matulonis. Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5507).
View in: PubMed

J. Liu, M. S. Hirsch, H. Lee, U. A. Matulonis. Protein expression and clinical features of ovarian cancer in the elderly. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(Abstract 5574).
View in: PubMed

U. Matulonis, H. Lee, W. Lu, A. Goodman, A. Rosulek, A. Doherty, A. Kornblith, T. Atkinson, C. Gibson, E. Dean-Clower, R. Penson. Randomized trial of acupuncture versus sham control for prevention of myelosuppression in patients with gynecologic malignancies. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 19524).
View in: PubMed

Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol. 2007 Mar; 104(3):727-31.
View in: PubMed

Morgan RJ, Alvarez RD, Armstrong DK, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Johnston C, Lancaster JM, Lele S, Matulonis U, Ozols RF, Remmenga SW, Sabbatini P, Soper J, Teng N. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Oct; 4(9):912-39.
View in: PubMed

Liu J, Matulonis U. Rational use of cytotoxic chemotherapy for recurrent ovarian cancer. J Natl Compr Canc Netw. 2006 Oct; 4(9):947-53.
View in: PubMed

Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10; 24(26):4324-32.
View in: PubMed

Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80.
View in: PubMed

Cannistra SA, Matulonis U, Penson R, Wenham R, Armstrong D, Burger RA, Mackey H, Douglas J, Hambleton J, McGuire W. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5006.
View in: PubMed

Campos SM, Parker L, Chen W, Bunnell CA, Atkinson T, Lee J, Matulonis UA, Harris LN, Krasner CN. Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085.
View in: PubMed

Roche M, Matulonis U, Krasner C, Penson R, Horowitz N, Berkenblit A, Findley M, Lee J, Horick N, Seiden MV. Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5081.
View in: PubMed

Glenn D, Ueland F, Bicher A, Dizon D, Gold M, Makhija S, Fleming GF, Matulonis U, McGuire WP, Lieberman G. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum-resistant ovarian cancer (OC): Preliminary safety data. J Clin Oncol. 2006 Jun 20; 24(18_suppl):13001.
View in: PubMed

Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
View in: PubMed

Mahoney J, Lee H, Foster R, Matulonis U, Duan Z, Seiden MV. Evaluation of serial serum IL-6 levels in women with newly diagnosed ovarian cancer on a prospective clinical trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5065.
View in: PubMed

Krasner CN, Seiden MV, Fuller AF, Roche M, Verrill CL, D'Amato F, Tretyakov O, Tyburski K, Matulonis UA, Supko JG. Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5008.
View in: PubMed

Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Penson RT. Long-term impact of chemotherapy on early stage ovarian cancer patients. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5024.
View in: PubMed

Littell RD, Hallonquist H, Matulonis U, Seiden MV, Berkowitz RS, Duska LR. Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma. Gynecol Oncol. 2006 Nov; 103(2):570-4.
View in: PubMed

Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4.
View in: PubMed

Joyce Liu and Ursula Matulonis. End of life Care. Muss, Johnson, and Hunter (eds.): Multidisciplinary Treatment and Management of Cancer in the Elderly . 2006.
View in: PubMed

D. Glenn, F. Ueland, A. Bicher, D. Dizon, M. Gold, S. Makhija, G. F. Fleming, U. Matulonis, W. P. McGuire, G. Lieberman. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum-resistant ovarian cancer (OC): preliminary safety data. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 13001).
View in: PubMed

U. A. Matulonis, A. Kornblith, H. Lee, J. Bryan, C. Gibson, C. Wells, J. Lee, L. Sullivan, R. T. Penson. Long-term impact of chemotherapy on early stage ovarian cancer patients. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5024).
View in: PubMed

S. M. Campos, L. Parker, W. Chen, C. A. Bunnell, T. Atkinson, J. Lee, U. A. Matulonis, L. N. Harris, C. N. Krasner. Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5085).
View in: PubMed

S. M. Campos, L. Parker, W. Chen, C. A. Bunnell, T. Atkinson, J. Lee, U. A. Matulonis, L. N. Harris, C. N. Krasner. Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5085).
View in: PubMed

J. Mahoney, H. Lee, R. Foster, U. Matulonis, Z. Duan, M. V. Seiden. Evaluation of serial serum IL-6 levels in women with newly diagnosed ovarian cancer on a prospective clinical trial. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5065).
View in: PubMed

M. Roche, U. Matulonis, C. Krasner, R. Penson, N. Horowitz, A. Berkenblit, M. Findley, J. Lee, N. Horick, M. V. Seiden, Dana Farber/harvard Cancer Center. Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5081).
View in: PubMed

Ursula Matulonis, Susana Campos, Linda Duska, Carolyn Krasner, Tina Atkinson, Richard Penson, Michael Seiden, Arlan Fuller, Annekathryn Goodman Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA . Phase I/II Dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer . SGO. 2006; (abstract 161).
View in: PubMed

Daniela Matei, Michael Gordon, Carol Aghajanian, Ursula Matulonis, Molly Brewer, Gini Fleming, John Hainsworth, Augustin Garcia, Mark Pegram, Beth Karlan Indiana University, Indianapolis, IN; University of Arizona, Phoenix, AZ; Memorial Sloan Kettering, New York, NY; Harvard Medical School, Boston, MA; University of Arizona, Tucson, AZ; University of Chicago, Chicago, IL; Sarah Cannon Cancer Center, Nashville, TN; Cedars Sinai Medical Center, Los Angeles, CA; UCLA, Los Angeles, CA . Clinical Activity of Single Agent Pertuzumab (rhuMab 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer (OC): Potential Predictive Relationship with Tumor HER2 Activation Status. . SGO. 2006; 20(abstract 20).
View in: PubMed

S. A. Cannistra, U. Matulonis, R. Penson, R. Wenham, D. Armstrong, R. A. Burger, H. Mackey, J. Douglas, J. Hambleton, W. McGuire. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5006).
View in: PubMed

C. N. Krasner, M. V. Seiden, A. F. Fuller, M. Roche, C. L. Verrill, F. D'Amato, O. Tretyakov, K. Tyburski, U. A. Matulonis, J. G. Supko, Dana Farber/harvard Cancer Center. Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5008).
View in: PubMed

R. T. Penson, S. A. Cannistra, M. V. Seiden, C. N. Krasner, U. A. Matulonis, N. S. Horowitz, S. Berlin, D. S. Dizon, H. Lee, S. M. Campos, n. representing members of the Dana Farber Harvard Ca. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5020).
View in: PubMed

Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005 Dec; 30(6):563-9.
View in: PubMed

Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol. 2006 Apr; 101(1):55-61.
View in: PubMed

Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41.
View in: PubMed

Golshan M, Kuten A, William J, Richardson A, Modarressi A, Matulonis U. Metaplastic carcinoma of the breast with neuroglial differentiation. Breast. 2006 Aug; 15(4):545-9.
View in: PubMed

Anna Berkenblita, i, , , Ursula A. Matulonisb, i, Joan F. Kroenerc, Bruce J. Dezubea, i, Gil N. Lamd, Luceli C. Cuasaye, Nils Brünnerf, Terence R. Jonesg, Michael H. Silvermanh and Michael A. Goldj . Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial . Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial. 2005; 99(1):50-57.
View in: PubMed

Berkenblit A, Matulonis UA, Kroener JF, Dezube BJ, Lam GN, Cuasay LC, Brünner N, Jones TR, Silverman MH, Gold MA. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol. 2005 Oct; 99(1):50-7.
View in: PubMed

Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005 Nov; 99(2):393-9.
View in: PubMed

Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer. 2005 Jul 11; 93(1):54-9.
View in: PubMed

Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6.
View in: PubMed

Krasner CN, Debernardo RL, Findley M, Penson R, Matulonis U, Atkinson T, Roche M, Seiden MV. Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5063.
View in: PubMed

Matulonis UA, Campos S, Krasner C, Duska L, Penson RP, Falke R, Roche M, Smith LM, Lee H, Seiden MV. A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5010.
View in: PubMed

Penson RT, Krasner CN, Seiden MV, Atkinson T, Kornblith A, Campos S, Klein A, Matulonis U. Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5159.
View in: PubMed

Lee CW, Matulonis UA, Campos SM, Gross AH, Hayes CM, Keenan KT, Castells MC. Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: A protocol effective in patients with gynecologic malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5090.
View in: PubMed

Seiden M, Burris HA, Matulonis U, Hall J, Armstrong D, Speyer J, Tillner J, Weber D, Muggia F. A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):3151.
View in: PubMed

Matulonis U, Abrahm JL. Cancer of the ovary. N Engl J Med. 2005 Mar 24; 352(12):1268-9; author reply 1268-9.
View in: PubMed

Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005 Mar; 96(3):824-9.
View in: PubMed

C. N. Krasner, R. L. Debernardo, M. Findley, R. Penson, U. Matulonis, T. Atkinson, M. Roche, M. V. Seiden. Phase II Trial of Anastrazole in Combination with Gefitinib in Women with Asymptomatic Mullerian Cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5063).
View in: PubMed

C. Lee, U. A. Matulonis, S. M. Campos, A. H. Gross, C. M. Hayes, K. T. Keenan, M. C. Castells. Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: a protocol effective in patients with gynecologic malignancies. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5090).
View in: PubMed

U. A. Matulonis, S. Campos, C. Krasner, L. Duska, R. P. Penson, R. Falke, M. Roche, L. M. Smith, H. Lee, M. V. Seiden. A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5010).
View in: PubMed

R. T. Penson, C. N. Krasner, M. V. Seiden, T. Atkinson, A. Kornblith, S. Campos, A. Klein, U. Matulonis. Long-acting octreotide (Sandostatin LAR®Depot) for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5159).
View in: PubMed

M. S. Gordon, D. Matei, C. Aghajanian, U. A. Matulonis, M. A. Brewer, G. F. Fleming, J. D. Hainsworth, A. A. Garcia, M. Pegram, B. Y. Karlan. Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5051).
View in: PubMed

Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan; 96(1):198-203.
View in: PubMed

M. Seiden, H. Burris, U. Matulonis, J. Hall, D. Armstrong, J. Speyer, J. Tillner, D. Weber, F. Muggia. A Phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 3151).
View in: PubMed

C. Lee, U. A. Matulonis, S. M. Campos, A. H. Gross, C. M. Hayes, K. T. Keenan, M. C. Castells. Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: a protocol effective in patients with gynecologic malignancies. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5090).
View in: PubMed

Anna Berkenblita, Michael V. Seidenb, Ursula A. Matulonisc, Richard T. Pensonb, Carolyn N. Krasnerb, Maria Rocheb, Lisa Mezzettib, Tina Atkinsonc and Stephen A. Cannistraa, , . A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer . Gynecologic Onlology. 2004; 95(3):624-631.
View in: PubMed

Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004 Dec; 95(3):624-31.
View in: PubMed

Morgan RJ, Alvarez RD, Armstrong DK, Chen LM, Copeland L, Fiorica J, Fowler J, Gaffney DK, Gershenson D, Greer BE, Grendys EC, Johnston C, Lele S, Matulonis UA, Molpus KL, Ozols RF, Sabbatini P, Santoso JT, Soper J, Teng N. Ovarian cancer clinical practice guidelines. J Natl Compr Canc Netw. 2004 Nov; 2(6):526-47.
View in: PubMed

Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol. 2004 Nov; 95(2):370-6.
View in: PubMed

Bajetta E, Vercammen E, Reinhardt U, Janmohamed R, da Costa RM, Matulonis U, Guastalla JP. Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy. Tumori. 2004 Sep-Oct; 90(5):449-57.
View in: PubMed

Penson RT, Dignan F, Seiden MV, Lee H, Gallagher CJ, Matulonis UA, Olson K, Gibbens I, Gore ME. Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):427-35.
View in: PubMed

Matulonis U, Krasner C, Atkinson T, Penson R. Long-acting octreotide for the treatment of symptoms of bowel obstruction and intermittent obstruction in advanced ovarian cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5148.
View in: PubMed

Penson RT, Seiden MV, Campos SM, Krasner CN, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5151.
View in: PubMed

Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
View in: PubMed

Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004 Apr 15; 22(8):1480-90.
View in: PubMed

Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, Sivret J, Rusk J, Barrett E. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol. 2004 Apr; 93(1):229-32.
View in: PubMed

Matulonis UA. End of life issues in older patients. Semin Oncol. 2004 Apr; 31(2):274-81.
View in: PubMed

U. Matulonis, C. Krasner, T. Atkinson, R. Penson; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA. Long-acting octreotide for the treatment of symptoms of bowel obstruction and intermittent obstruction in advanced ovarian cancer. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; Vol 22, No 14S (July 15 Supple(abstract 5148).
View in: PubMed

R. T. Penson, M. V. Seiden, S. M. Campos, C. N. Krasner, A. F. Fuller, A. Goodman, M. Roche, A. Willman, A. Muzikansky, U. A. Matulonis; Massachusetts General Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA. A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; Vol 22, No 14S (July 15 Supple(abstract 5151).
View in: PubMed

del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003 Dec; 91(3):596-602.
View in: PubMed

Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003 Nov; 91(2):293-8.
View in: PubMed

Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF, Wilson KS, Puchalski TA, Supko JG, Seiden MV. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol. 2003 Sep; 90(3):610-8.
View in: PubMed

U. Matulonis, S. Campos, M. Seiden, C. Krasner, A. Fuller, L. Duska, R. Berkowitz, T. Collela, A. Crowe, A. Goodman; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA. Phase I study of cisplatin and gemcitabine for recurrent cervix cancer following primary radiotherapy or newly diagnosed metastatic cervix cancer. Proc Am Soc Clin Oncol. 2003; 22(abstr 1872).
View in: PubMed

Matulonis U.A. Gynecologic Cancers. Atlas of Diagnostic Oncology, Arthur Skarin, editor. 2003.
View in: PubMed

R. T. Penson, F. Dignan, H. Lee, M. V. Seiden, C. J. Gallagher, U. A. Matulonis, I. Gibbens, K. Olson, M. E. Gore; Massachusetts General Hospital, Boston, MA; St Bartholomew's Hospital, London, UK; Dana-Farber Cancer Institute, Boston, MA; Royal Marsden Hospital, London, UK. Attitudes to chemotherapy in patients with ovarian cancer. Proc Am Soc Clin Oncol. 2003; 22(abstract abstr 1888).
View in: PubMed

Matulonis U.A. Significance of Positive Peritoneal Cytology in Women with Endometrial Cancer. ACS Endometrial Cancer. 2003.
View in: PubMed

Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002 Sep; 86(3):302-10.
View in: PubMed

Diller L, Medeiros Nancarrow C, Shaffer K, Matulonis U, Mauch P, Neuberg D, Tarbell NJ, Litman H, Garber J. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol. 2002 Apr 15; 20(8):2085-91.
View in: PubMed

Marcus O Butler, Michael Seiden, Martin Mihm, Susana M Campos, Linda Duska, Donald Goldstein, Annekathryn Goodman, Donna Neuberg, Najmosama Nikrui, Ursula Matulonis, Michael Muto, Richard Penson, Iain Webb, Arlan Fuller, Ross Berkowitz, Lee Nadler, Glenn Dranoff, Dana-Farber Cancer Inst, Boston, MA; Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA. A phase I study of vaccination with lethally irradiated, autologous ovarian cancer cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor (GVAX). Proc Am Soc Clin Oncol. 2002; 21(abstr 1840).
View in: PubMed

Richard T Penson, Joseph P Eder, Arlan F Fuller Jr., Jeffrey G Supko, Ursula A Matulonis, Susana M Campos, Leonard J Appleman, Maria Roche, Aimee Harris, Michael V Seiden, Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Inst, Boston, MA. A Phase I trial of continual sequential oral etoposide and infusional topotecan. Proc Am Soc Clin Oncol. 2002; 21(abstr 2168).
View in: PubMed

Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67.
View in: PubMed

Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in: PubMed

Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001 May; 81(2):206-12.
View in: PubMed

Susana M. Campos, Richard T. Penson, Ursula A. Matulonis, Ross S. Berkowitz, Linda R. Duska, Arlan F. Fuller, AnneKathryn Goodman, Najmosama Nikrui, Ellen E. Sheets, Michael Muto, Kimberley M. MacNeill, Julia C. Sivret, Maria Roche, Kara Wilson, Jeffrey G. Supko, Michael V. Seiden, Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA. A Phase II and Pharmacokinetic/Dynamic Study of Doxil and Weekly Paclitaxel Chemotherapy for Recurrent Müllerian Tumors. Proc Am Soc Clin Oncol. 2001; 20(abstr 2524).
View in: PubMed

Ursula Matulonis, Susanna Campos, Linda Duska, Arlan Fuller, Roberta Falke, Stacy Gore, Ross Berkowitz, Maria Roche, Diane Finkelstein, Julia Sivret, Tina Colella, Richard Penson, Ellen Sheets, Michael Seiden, Dana-Farber/Partners CancerCare, Boston, MA; Harvard Vanguard Medical Associates, Boston, MA. Triple Doublet Chemotherapy for the Treatment of Mullerian Malignancies. Proc Am Soc Clin Oncol. 2001; 20(abstr 846).
View in: PubMed

Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2000 May; 77(2):271-7.
View in: PubMed

Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
View in: PubMed

Harold Burstein, Irene Kuter, Paul Richardson, Susana Campos, Leroy Parker, Ursula Matulonis, Lyndsay Harris, Judy Garber, Jerry Younger, Craig Bunnell, Lawrence Shulman, Eric Winer. Herceptin and Vinorelbine for HER2-Positive Metastatic Breast Cancer: A Phase II Study. Proc Am Soc Clin Oncol. 2000; 19(abstr 392).
View in: PubMed

Craig Bunnell, Leroy Parker, Ursula Matulonis, Lawrence Shulman, Anthony Elias, Lyndsay Harris, Rochelle Scheib, Harold Burstein, Susana Campos, Jerry Younger, Irene Kuter, Eric Winer. A Phase I Study of Cyclophosphamide, Doxorubicin, and Eniluracil/5-FU in Women with Advanced Breast Cancer: Preliminary Results. Proc Am Soc Clin Oncol. 2000; 19(abstr 444).
View in: PubMed

Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 2000 Jan; 10(1):33-41.
View in: PubMed

Arlan Fuller, Richard Penson, Jeffrey Supko, Ursula Matulonis, Ross Berkowitz, Annekatherine Goodman, Susana Campos, Kimberly MacNeill, Karen Borden, Sarah Cook, Steven Skates, Michael Seiden. A Phase I/II and Pharmacokinetic Study of 96-Hour Infusional Topotecan and Paclitaxel Chemotherapy for Recurrent Müllerian Tumors. Proc Am Soc Clin Oncol. 2000; 19(abstr 1552).
View in: PubMed

Ursula Matulonis, Susanna Campos, Michael Seiden, Arlan Fuller, Kimberly MacNeill, AnnMarie Charbonnier, Ross Berkowitz, Annekathryn Goodman. Phase I Study of Cisplatin and Gemcitabine for Recurrent Cervix Cancer Following Primary Radiotherapy. Proc Am Soc Clin Oncol. 2000; 19(abstr 1571).
View in: PubMed

Susana Campos, Richard Penson, Ursula Matulonis, Ross Berkowitz, Linda Duska, Arlan Fuller, Annekatherine Goodman, Najmosama Nikrui, Sheets Ellen, Michael Muto, Kimberly MacNeill, Cameo Genovese. A Phase II and Pharmacokinetic/Dynamic Study of Doxil and Weekly Paclitaxel Chemotherapy for Recurrent Müllerian Tumors. Proc Am Soc Clin Oncol. 2000; 19(abstr 1623).
View in: PubMed

Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6.
View in: PubMed

Campos Susana , Penson Richard , MacNeill Kimberley , Berkowitz Ross , Cook Sarah , Fuller Arlan , Goodman Anne , Najmosam Nikrui, Shulman Laurance , Matulonis Ursula , Seiden Michael . A Retrospective Analysis of the Clinical Utility of Doxil in Recurrent Ovarian Cancer (ROC). (Meeting abstract). 1999 ASCO Meeting. 1999; ASCO Meeting(abstract 1434).
View in: PubMed

N Tung, J Niloff, M Quartulli, Y Kim, U Matulonis, M Seiden, R Berkowitz, S Lee, SA Cannistra. A Phase I Study of Carboplatin, Taxol[Superscript TM], Etoposide, and Cyclophosphamide (CTEC) with Filgrastim as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer (Meeting abstract). 1999 Asco Meeting. 1999; ASCO(abstract 1417).
View in: PubMed

Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, Hayes DF, Winer EP. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1999; 43(1):68-72.
View in: PubMed

Matulonis U.A. Breast Cancer: Modifiable Lifestyle Risk Factors, in Lifestyle Medicine. Editor: James M. Rippe. 1999.
View in: PubMed

Penson Richard , Supko Jeffrey , Cook Sarah , MacNeill Kimberley , Thoma Makastorsis, Bonenfant Jill , Borden Karen , Berkowitz Ross , Fuller Arlan , Goodman Anne , Najmosm Nikrui, Matulonis Ursula , Seiden Michael . A Phase I/II and Pharmacokinetic Study of 96 Hour Infusional Topotecan and Paclitaxel Chemotherapy for Relapsed Epithelial Ovarian Cancer. (Meeting abstract). 1999 ASCO Meeting. 1999; ASCO Meeting(abstract 1477).
View in: PubMed

HJ Burstein, J Younger, CA Bunnell, UA Matulonis, JE Garber, LN Shulman, LM Parker, R Scheib, K Clarke, K Fowler, R Gelman, EP Winer. Weekly Docetaxel (Taxotere[trade]) for Metastatic Breast Cancer: A Phase II Trial (Meeting abstract). 1999 ASCO Meeting. 1999; ASCO Meeting(abstract 484).
View in: PubMed

Matulonis U. The Molecular Basis of Cancer: A review. Oncology. 1996; 10:71.
View in: PubMed

Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol. 1996 Feb 01; 156(3):1126-31.
View in: PubMed

CS Smith, K Shaffer, J Garber, P Mauch, D Mills, CL Shapiro, UA Matulonis, NJ Tarbell, L Diller. Breast cancer screening in young women who have been treated for Hodgkin's disease (Meeting abstract). 1996 ASCO Meeting. 1996; ASCO Meeting(abstract 1659).
View in: PubMed

Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 1995 May 01; 85(9):2507-15.
View in: PubMed

Okuda K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol. 1994 Oct; 22(11):1111-7.
View in: PubMed

Matulonis UA, Griffin JD, Canellos GP. Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. Am J Hematol. 1994 Apr; 45(4):283-7.
View in: PubMed

Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993 Oct; 21(11):1460-6.
View in: PubMed

Matulonis U, Rosenfeld CS, Shadduck RK. Prevention of Legionella infections in a bone marrow transplant unit: multifaceted approach to decontamination of a water system. Infect Control Hosp Epidemiol. 1993 Oct; 14(10):571-5.
View in: PubMed

Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, Griffin JD. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood. 1992 May 01; 79(9):2215-20.
View in: PubMed

Weiselberg L, Matulonis U, McGarvey E, Roberts B, Lichtman S, Allen S, Vinciguerra V, Teichberg S. Stereologic analysis of monocytes and their subcellular organelles in patients with acute monocytic and myelomonocytic leukemia. Lab Invest. 1990 Sep; 63(3):405-12.
View in: PubMed

Weiselberg L., Matulonis U., McGarvey E., Roberts B., Lichtman S., Allen S., Vinciguerra V., and Teichberg S . Stereologic Analysis of Monocytes and their Subcellular Organelles in patients wit acute monocytic and myelomonocytic leukemia. . Laboratory Investigation. 1990; 63(3):405-12.
View in: PubMed

Top